Integra LifeSciences (NASDAQ:IART) Reaches New 12-Month Low After Analyst Downgrade

Key Points

• Shares hit a new 52-week low (traded as low as $8.91) after Citigroup cut its price target from $11 to $9 and maintained a sell rating, driving a sharp intraday decline.
• Analyst sentiment is broadly negative: the stock has an average rating of "Reduce" (2 Buys, 2 Holds, 3 Sells) and an average target price of $14.40, with other brokers also trimming targets and ratings recently.
• Operationally, Integra beat Q4 estimates (EPS $0.83 vs. $0.79; revenue $434.9M) but still shows a negative net margin (-31.58%); management guided FY2026 EPS of 2.30–2.40, while institutional ownership is high (~84.8%).

Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report)'s share price hit a new 52-week low during trading on Thursday after Citigroup lowered their price target on the stock from $11.00 to $9.00. Citigroup currently has a sell rating on the stock. Integra LifeSciences traded as low as $8.91 and last traded at $8.9750, with a volume of 301019 shares traded. The stock had previously closed at $9.61.

A number of other brokerages also recently issued reports on IART. Wells Fargo & Company cut their price objective on Integra LifeSciences from $13.00 to $12.00 and set an "equal weight" rating for the company in a research report on Friday, February 27th. Wall Street Zen lowered shares of Integra LifeSciences from a "buy" rating to a "hold" rating in a research note on Saturday, March 7th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Integra LifeSciences in a research report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Reduce" and an average target price of $14.40.

Hedge Funds Weigh In On Integra LifeSciences

Several hedge funds have recently bought and sold shares of IART. Rubric Capital Management LP grew its position in Integra LifeSciences by 58.4% in the 2nd quarter. Rubric Capital Management LP now owns 7,353,934 shares of the life sciences company's stock valued at $90,233,000 after acquiring an additional 2,710,262 shares in the last quarter. Paradigm Capital Management Inc. NY boosted its stake in shares of Integra LifeSciences by 57.5% in the second quarter. Paradigm Capital Management Inc. NY now owns 2,181,500 shares of the life sciences company's stock valued at $26,767,000 after purchasing an additional 796,300 shares during the period. Invenomic Capital Management LP grew its holdings in shares of Integra LifeSciences by 78.3% in the fourth quarter. Invenomic Capital Management LP now owns 1,055,941 shares of the life sciences company's stock valued at $13,115,000 after purchasing an additional 463,729 shares in the last quarter. Kotler Kevin acquired a new position in shares of Integra LifeSciences in the fourth quarter valued at approximately $5,309,000. Finally, SG Americas Securities LLC purchased a new stake in Integra LifeSciences during the 4th quarter worth approximately $4,722,000. Institutional investors and hedge funds own 84.78% of the company's stock.

Integra LifeSciences Stock Performance

The company has a current ratio of 2.54, a quick ratio of 1.46 and a debt-to-equity ratio of 1.66. The company has a market capitalization of $699.48 million, a price-to-earnings ratio of -1.33 and a beta of 1.02. The stock's fifty day simple moving average is $11.54 and its 200-day simple moving average is $12.95.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The life sciences company reported $0.83 EPS for the quarter, topping the consensus estimate of $0.79 by $0.04. The business had revenue of $434.93 million during the quarter, compared to the consensus estimate of $429.62 million. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The company's quarterly revenue was down 1.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.97 earnings per share. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. Analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.